Objective To compare the visual outcomes of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in a real-world setting. Methods and analysis Retrospective analysis of data from the Tasmanian Ophthalmic Biobank database. The median change in best-corrected visual acuity (BCVA) between baseline and 12 months post initiating intravitreal anti-VEGF treatment were compared between the three diseases. Final BCVA, central macular thickness (CMT), cumulative number of injections and overall predictors of change in BCVA and CMT were also determined. Results At 12 months, change in BCVA was significantly different between nAMD, DMO and RVO cohorts (p=0.032), with lower median change for DMO (2 letters, range −5 to 20) than for RVO (11 letters, range −20 to 35). Likewise, CMT change was significantly different between the three cohorts (p=0.022), with a smaller reduction in CMT in DMO (−54 µm, range −482 to 50) than RVO patients (−137 µm, range −478 to 43; p=0.033). Total number of injections received (p=0.028) and final BCVA score (p=0.024) were also significantly different between the groups. Baseline BCVA was a negative predictor (p=0.042) and baseline CMT a positive predictor (p<0.001) of outcome. After adjusting for baseline BCVA and CMT, diagnosis of nAMD or RVO was a predictor of visual improvement compared with the DMO. Conclusions At the end of 12 months, nAMD and RVO cohorts had the greatest improvement in BCVA, however the final BCVA for DMO was significantly better than for nAMD. Data are available upon request.

中文翻译：

---

在临床实践中比较玻璃体内抗血管内皮生长因子注射治疗新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞患者的视力和黄斑厚度

目的比较玻璃体内抗血管内皮生长因子 (anti-VEGF) 注射在新生血管性年龄相关性黄斑变性 (nAMD)、糖尿病性黄斑水肿 (DMO) 和视网膜静脉阻塞 (RVO) 中的视觉效果。方法和分析 对来自塔斯马尼亚眼科生物银行数据库的数据进行回顾性分析。比较了三种疾病在基线和开始玻璃体内抗 VEGF 治疗后 12 个月之间最佳矫正视力 (BCVA) 的中位变化。还确定了最终的 BCVA、中央黄斑厚度 (CMT)、累积注射次数以及 BCVA 和 CMT 变化的总体预测因子。结果 在 12 个月时，nAMD、DMO 和 RVO 队列之间的 BCVA 变化显着不同（p=0.032），DMO 的中位数变化较低（2 个字母，范围 -5 到 20）而不是 RVO（11 个字母，范围 -20 到 35）。同样，三个队列之间的 CMT 变化显着不同（p=0.022），DMO 中 CMT 的降低（-54 µm，范围 -482 至 50）比 RVO 患者（-137 µm，范围 -478 至 43； p = 0.033)。接受的注射总数 (p=0.028) 和最终 BCVA 评分 (p=0.024) 在各组之间也存在显着差异。基线 BCVA 是阴性预测因子（p=0.042），基线 CMT 是阳性预测因子（p<0.001）。在调整基线 BCVA 和 CMT 后，与 DMO 相比，nAMD 或 RVO 的诊断是视力改善的预测指标。结论 在 12 个月末，nAMD 和 RVO 队列的 BCVA 改善最大，但 DMO 的最终 BCVA 明显优于 nAMD。数据可应要求提供。